Rare histological subtypes of bladder cancer in clinical practice: a case series
- 作者: Paychadze A.1, Golubeva S.1, Kamalova M.1
-
隶属关系:
- Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre
- 期: 卷 25, 编号 2 (2023)
- 页面: 229-235
- 栏目: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/132822
- DOI: https://doi.org/10.26442/18151434.2023.2.202185
- ID: 132822
如何引用文章
全文:
详细
Non-urothelial tumors account for less than 5% of all bladder malignant neoplasms. The most common non-urothelial tumor is squamous cell carcinoma, often found in the Middle East (about 30% of all cases of bladder cancer – BC) due to the spread of schistosomiasis. The glandular type is the second most common non-urothelial morphological variant; it includes 5 tumor subtypes (intestinal, mucinous, signet ring cell, mixed, and adenocarcinoma not otherwise specified). The neuroendocrine variant is divided into 4 subgroups (small cell, large cell, highly differentiated, and paragangliomas), of which small cell is the most common, though still rare, and accounts for only about 1% of all BCs. The article presents the clinical cases of three rare BC subtypes: squamous cell, glandular, and neuroendocrine. In the first clinical case, a radical cure of a patient with signet ring cell BC was described: at the first stage, the bladder, prostate, and vesicles were removed with a cystoplasty using a small intestine segment according to the Bricker technique with an extended pelvic lymph node dissection; the second stage included 8 courses of adjuvant drug treatment according to the XELOX regimen. In the second clinical case, the treatment of the metastatic neuroendocrine BC was described using the following regimens: EP (etoposide + cisplatin), carboplatin + irinotecan, GemOx (gemcitabine + oxaliplatin). The third clinical case described a patient with bladder squamous cell carcinoma. The stage I treatment was based on the GC regimen; at stage II, the bladder, prostate, and vesicles were removed with intestinal orthotopic cystoplasty and extended lymph node dissection; due to progression revealed during the follow-up examination, the patient received another GC course. Although non-urothelial BCs are very rare, studies are currently being conducted on the effectiveness of immunotherapy and targeted therapy in treating this cohort of patients.
作者简介
Anna Paychadze
Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre
Email: paiann@mail.ru
ORCID iD: 0000-0001-7912-8055
Cand. Sci. (Med.)
俄罗斯联邦, MoscowSofia Golubeva
Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre
Email: Golu-sofya@ya.ru
врач-онколог отделения комбинированных методов лечения №1
俄罗斯联邦, MoscowMilyausha Kamalova
Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre
编辑信件的主要联系方式.
Email: milyausha.kamalova.97@mail.ru
ORCID iD: 0000-0003-0495-8585
Resident Physician
俄罗斯联邦, Moscow参考
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2020;68(6):209-9. doi: 10.3322/caac.21660
- Quek ML, Nichols PW, Yamzon J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the University of Southern California experience. J Urol. 2005;174(1):93-6. doi: 10.1097/01.ju.0000162085.20043.1f
- Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ имени П.А Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022 [Sostoianiie onkologicheskoi pomoshchi naseleniiu Rossii v 2021 godu. Pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi. Moscow: MNIOI im. P.A.Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022 (in Russian)].
- Рева И.А., Нюшко К.М., Плеханова Е.Н., и др. Лейомиосаркома мочевого пузыря, исходящая из мышечных элементов слизистой оболочки мочевого пузыря (клинический случай). Онкоурология. 2022;18(1):106-11 [Reva IA, Nyushko KM, Plekhanova EN, et al. Bladder leiomyosarcoma originating from the muscular elements of the bladder mucosa (clinical case). Cancer Urology. 2022;18(1):106-11 (in Russian)]. doi: 10.17650/1726-9776-2022-18-1-106-111
- Manunta A, Vincendeau S, Kiriakou G, et al. Non-transitional cell bladder carcinomas. BJU Int. 2005;95(4):497-502. doi: 10.1111/j.1464-410X.2005. 05327.x
- Abol-Enein H, Kava BR, Carmack AJK. Nonurothelial cancer of the bladder. Urology. 2007;69(1):93-104. doi: 10.1016/j.urology.2006.08.1107
- Moschini M, D’Andrea D, Korn S, et al. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol. 2017;14(11):651-68. doi: 10.1038/nrurol.2017.125
- Baumeister P, Zamboni S, Mattei A, et al. Histological variants in nonmuscle invasive bladder cancer. Transl Androl Urol. 2019;8(1):34-8. doi: 10.21037/tau.2019.01.09
- Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer. 1991;67(8):2165-72. doi: 10.1002/1097-0142(19910415)67:82165::aid-cncr2820670827>3.0.co;2-m
- Sved P, Gomez P, Manoharan M, et al. Small cell carcinoma of the bladder. BJU Int. 2004;94(1):12-7. doi: 10.1111/j.1464-410X.2003.04893.x
- Гладков О.А., Зуков Р.А., Матвеев В.Б., и др. Практические рекомендации по лекарственному лечению рака мочевого пузыря. Злокачес- твенные опухоли: Практические рекомендации RUSSCO #3s2. 2021;11:32 [Gladkov OA, Zukov RA, Matveiev VB, et al. Prakticheskiie rekomendatsii po lekarstvennomu lecheniiu raka mochevogo puzyria. Zlokachestvennyie opukholi: Prakticheskiie rekomendatsii RUSSCO #3s2. 2021;11:32 (in Russian)]. doi: 10.18027/2224-5057-2021-11-3s2–32
- Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy foradvanced bladder cancer. J Urol. 2005;174(1):14-20. doi: 10.1097/01.ju.0000162039.38023.5f
- El Ammari JE, Ahsaini M, Riyach O, et al. Primary signet-ring cell carcinoma of the urinary bladder successfully managed with cisplatin and gemcitabine: A case report. J Med Case Rep. 2013;7:37.
- Аббасова Д.В., Поликарпова С.Б., Козлов Н.А., и др. Нейроэндокринные опухоли мочевыделительной системы: обзор литературы. Онкоурология. 2019;15(2):126-33 [Abbasova DV, Polikarpova SB, Kozlov NA, et al. Neuroendocrine tumors of the urinary system: literature review. Cancer Urology. 2019;15(2):126-33 (in Russian)]. doi: 10.17650/1726-9776-2019-15-2-126-133
- Cheng L, Pan CX, Yang XJ, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 2004;101(5):957-62. doi: 10.1002/cncr.20456
- Lohrisch C, Murray N, Pickles T, Sullivan L. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer. 1999;86(11):2346-52.
- Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005;103(6):1172-8. doi: 10.1002/cncr.20903
- Shapur NK, Katz R, Pode D, et al. Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare Tumors. 2011;3(2):e22. doi: 10.4081/rt.2011.e22
- Galsky MD, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007;69(2):255-9. doi: 10.1016/j.urology.2006.10.029
- Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001;19(9):2527-33. doi: 10.1200/jco.2001.19.9.2527
- Apolo AB, Nadal R, Tomita Y, et al. Cabozantinib in patients with platinumrefractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncol. 2020;21(8):1099-109. doi: 10.1016/s1470-2045(20)30202-3.